Although Oxford would not disclose information about the patient's illness due to participant confidentiality, an AstraZeneca spokesman said earlier this week that a woman had developed neurological symptoms that prompted the pause.
The vaccine being developed by Oxford and AstraZeneca is widely perceived to be one of, if not the strongest contender among the dozens of coronavirus vaccines in various stages of testing around the world. This is the second known hold of studies of the AstraZeneca vaccine.
Biopharmaceutical giant AstraZeneca and the University of Oxford on Saturday said that clinical trials for their coronavirus vaccine have resumed in the United Kingdom after the Medicines Health Regulatory Authority's (MHRA) confirmed that the trials were safe.
Dr Chiu said: "We have evidence that delivering influenza vaccines via a nasal spray can protect people against flu as well as help to reduce the transmission of the disease". For instance, Indian Immunologicals Ltd, a human and animal vaccines maker that was set up by NDDB, has a new 20 million single dose (200 million multi-dose) fill finish capacity coming up at Genome Valley on Hyderabad outskirts that it is ready to deploy for third-party Covid-19 vaccine manufacturing.
Hassan Valley, an epidemiologist from La Trobe University, suggests rather than this transitory pause being a cause for concern it should instead offer reassurance that this vaccine trial is being conducted using optimal safety precautions. Trials are also planned in Japan and Russian Federation. The deal was signed as part of Operation Warp Speed, the Trump administration's effort to accelerate development and production of vaccines and treatments to fight the coronavirus.
The offices of British-Swedish multinational pharmaceutical and biopharmaceutical company AstraZeneca PLC in Macclesfield, England, July 21, 2020.
The Medicines Health Regulatory Authority (MHRA) has said it is now safe to continue the trial. "All trial investigators and participants will be updated with relevant information and this will be disclosed on global clinical registries, according to the clinical trial and regulatory standards", the firm said. However, it has not been confirmed that it's indeed transverse myelitis and more tests are being carried.
"I think one would have to say that we're on the edge of losing control", Mark Walport, the British government's former chief scientific adviser, told BBC radio.